{'fraction_non_alphanumeric': 0.014977973568281937, 'fraction_numerical': 0.014977973568281937, 'mean_word_length': 5.528735632183908, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Standardization of the Caffeine Halothane Muscle Contracture Test

On November 4 6 , 1987, 47 representatives from 24 North American malignant hyperthermia (MH) testing centers met in Lake Bluff, Illinois, to discuss development of a standardized protocol for skeletal muscle contracture testing using caffeine and halothane. The caffeine halothane contracture test is a screening test that requires use of fresh muscle and is used in the diagnosis of MH susceptibility. A standardized protocol for caffeine halothane contracture testing has been previously established in Europe by the European Malignant Hyperpyrexia Group (see p. 515). The European protocol differs in several minor aspects from the North American protocol, with the primary difference involving exposure of muscle to 2% rather than 3% halothane. This article represents the consensus achieved by the 47 representatives who shall hereafter be referred to as the North American MH Group who convened under the sponsorship of the Malignant Hyperthermia Association of the United States and the Malignant Hyperthermia Association. The recommended protocol of the North